Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Retiree Drug Coverage Is Stable Heading Into Medicare Rx, Caremark Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Employers have approached Caremark for help in sorting out what the Medicare drug benefit means, but have shown no indication that they will drop retiree coverage, the PBM says. Caremark predicts it will not participate as a stand-alone plan in the benefit, but it is willing to support health plans with administering the pharmacy benefit.

You may also be interested in...



Medicare “Average Sales Price” Rule Predicts $800 Mil. In Savings For 2005

CMS expects the shift from average wholesale price-based reimbursement to the ASP plus 6% formula to generate savings of $530 mil. to Medicare and $270 mil. to beneficiaries in 2005. The agency expects changes outlined in its proposed rule to bring “transparency and appropriateness” to its payments for Part B drugs.

Employer Options For Retiree Health Plans Outlined In Proposed Medicare Drug Rule

CMS is declining to predict whether the four retiree health coverage options available to employers and outlined in a Medicare proposed rule issued July 26 will be sufficient to stem the tide of employer dropouts

“Fallback” Plan Will Be Main Medicare Rx Program, Medco Predicts

The private sector is unlikely to offer stand-alone drug insurance plans under Medicare in 2006, Medco CEO David Snow predicted during the Goldman Sachs conference in Laguna Niguel, Calif. June 9

Topics

UsernamePublicRestriction

Register

OM004078

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel